Docket No.: 29729/38914

AMENDMENTS TO THE CLAIMS

1.-27. (Canceled)

- 28. (Currently amended) A method for the treatment or prophylaxis of a B-cell disorder in a subject, the method comprising administering to the subject an effective amount of an anti-LMA antibody that specifically binds LMA to inhibit the growth of, or kill, lymphoid cells in the subject.
- 29. (Previously presented) A method according to claim 28 wherein the B-cell disorder is a lymphoproliferative disorder selected from the group consisting of multiple myeloma, B cell lymphoma and macroglobulinemia.
- 30. (Previously presented) A method according to claim 28 wherein the B-cell disorder is multiple myeloma.
- 31. (Previously presented) A method according to claim 28 wherein the anti-LMA antibody is conjugated to a cytotoxic moiety or biological modifier.
- 32. (Previously presented) A method according to claim 34 wherein the cytotoxic moiety is a toxin, a chemotherapeutic agent, or a radioactive agent.
- 33. (Currently amended) A method for inhibiting the growth of or killing lymphoid cells in a subject, the method comprising administering to the subject an LMA ligand which specifically binds LMA and is conjugated to a cytotoxic moiety or biological modifier, under conditions sufficient for the binding of the LMA ligand conjugate to the lymphoid cells to inhibit the growth of, or to kill, the cells.
- 34. (Previously presented) A method according to claim 33 wherein the LMA ligand is anti-LMA antibody.
- 35. (Previously presented) A method according to claim 33 wherein the cytotoxic moiety is a toxin, a chemotherapeutic agent, or a radioactive agent.
- 36. (Previously presented) A method according to claim 28 which further comprises the step of treating the subject to reduce the level of free lambda light chains

Amendment dated December 22, 2008 Reply to Office Action of September 25, 2008

present in the fluid of the subject prior to administration of the anti-LMA antibody or LMA ligand conjugate.

Docket No.: 29729/38914

- 37. (Previously presented) A method according to claim 36 wherein the level of free light chains present in the serum of the subject is reduced by chemotherapy or plasmapheresis.
- 38. (Currently amended) A method for autologous hematopoietic cell transplantation in a subject, the method comprising (i) removing a hematopoietic progenitor cell population from the subject, (ii) treating the cell population with an anti-LMA antibody or LMA ligand conjugate, wherein the anti-LMA antibody or LMA ligand conjugate specifically binds LMA, and (iii) transplanting the treated cell population from step (ii) into the subject.
- 39. (Previously presented) A method according to claim 38 which further comprises intravenous infusion of anti-LMA antibody or LMA ligand conjugate into the subject.
- 40. (Currently amended) A method for localizing lymphoid cells in a subject, the method comprising administering to the subject an anti-LMA antibody or LMA ligand, allowing the antibody or ligand to bind to cells within the subject, and determining the location of the antibody or ligand within the subject, wherein the anti-LMA antibody or LMA ligand conjugate specifically binds LMA.
- 41. (Previously presented) A method according to claim 40 wherein the antibody or ligand is detectably labeled.
- 42. (Previously presented) A method according to claim 28 wherein the anti-LMA antibody is a chimeric antibody or a humanised antibody.
- 43. (Currently amended) An anti-LMA conjugated to a cytotoxic moiety or a biological modifier, wherein the anti-LMA antibody specifically binds LMA.
- 44. (Previously presented) An anti-LMA antibody according to claim 43 wherein the cytotoxic moiety is a toxin, a chemotherapeutic agent, or a radioactive agent.

Application No. 10/590,690 Amendment dated December 22, 2008 Reply to Office Action of September 25, 2008 Docket No.: 29729/38914

- 45. (Previously presented) An anti-LMA antibody according to claim 43 wherein the cytotoxic moiety is a nucleic acid molecule encoding a cytotoxic polypeptide.
- 46. (Previously presented) An anti-LMA antibody according to claim 43 wherein the biological response modifier is a lymphokine, a cytokine or an interferon.
- 47. (Currently amended) An anti-LMA antibody labeled with a detectable moiety, wherein the anti-LMA antibody specifically binds LMA.
- 48. (Currently amended) A pharmaceutical composition comprising an anti-LMA antibody or an LMA antigen conjugate and a pharmaceutically-acceptable carrier, diluent, or excipient, wherein the anti-LMA antibody or LMA ligand specifically binds LMA.